Compare DexCom, Inc. (DXCM) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Core High Dividend ETF — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while iShares Core High Dividend ETF trades at $28.73 (market cap $14.68B). The key difference: DexCom, Inc. is far larger — about 2.2× iShares Core High Dividend ETF's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 2,925,562). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares Core High Dividend ETF for 117 Days on average.
| DXCM | HDV | |
|---|---|---|
Market Cap | $31.86B | $14.68B |
Volume | 3,607,070 | 2,925,562 |
Sector | Health | — |
52-Week High | $92.34 | $29.93 |
52-Week Low | $54.84 | $23.64 |
Typical Hold Time | 62 Days | 117 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% on the day, with technical indicators showing a neutral to bearish bias. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. This shift creates heightened concentration risk with 62% of assets in just three sectors, offering a 3% yield that may not adequately compensate for reduced diversification according to Seeking Alpha analysis from September 28, 2026.
The outlook remains cautious as HDV's sector concentration and modest yield face headwinds from rising interest rates. While high-dividend ETFs are outperforming the S&P 500 in 2026 according to 24/7 Wall Street, HDV's structural changes introduce execution risk. Investors should weigh the trade-off between current income and long-term diversification benefits, particularly as the Fed continues tightening monetary policy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
